The Europe In Situ Hybridization Market would witness market growth of 6.5% CAGR during the forecast period (2022-2028).
The localization of gene expression in a cellular context is shown by in situ hybridization. A sample's known target mRNA or DNA sequence may be found using a labeled RNA or DNA probe to hybridize it. Then, an antibody may be used to recognize the label on the labeled RNA or DNA probe. Therefore, the probes may be utilized to find the mRNA's location and the expression of an interest gene.
Numerous congenital and acquired neurological disorders, including intellectual impairments, congenital malformations, and primary central nervous system tumors, have a molecular genesis involving structural and numerical changes to the healthy human diploid genome. Chromosome microarray analysis (CMA), also known as fluorescence in situ hybridization (FISH) and, more lately, microarray-based genomic hybridization techniques, are now regarded as essential tools for both clinical diagnosis and treatment of patients with these diseases as well as for scientific research.
The medical technology market in Germany is the largest in all of Europe. The German medical device industry, which accounts for around USD 35.8 billion yearly or 25.6% of the whole European market, is one of the most profitable healthcare markets in the world. The region's strong and well-developed medical technology sector is expected to demonstrate the adoption of ISH-type technologies. Thus, it is projected that the market for in situ hybridization will grow in the region due to the rising prevalence of cancer and the growing acceptability of cutting-edge medical technology.
The Germany market dominated the Europe In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $114.7 million by 2028.The UK market is anticipated to grow at a CAGR of 5.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.2% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
The localization of gene expression in a cellular context is shown by in situ hybridization. A sample's known target mRNA or DNA sequence may be found using a labeled RNA or DNA probe to hybridize it. Then, an antibody may be used to recognize the label on the labeled RNA or DNA probe. Therefore, the probes may be utilized to find the mRNA's location and the expression of an interest gene.
Numerous congenital and acquired neurological disorders, including intellectual impairments, congenital malformations, and primary central nervous system tumors, have a molecular genesis involving structural and numerical changes to the healthy human diploid genome. Chromosome microarray analysis (CMA), also known as fluorescence in situ hybridization (FISH) and, more lately, microarray-based genomic hybridization techniques, are now regarded as essential tools for both clinical diagnosis and treatment of patients with these diseases as well as for scientific research.
The medical technology market in Germany is the largest in all of Europe. The German medical device industry, which accounts for around USD 35.8 billion yearly or 25.6% of the whole European market, is one of the most profitable healthcare markets in the world. The region's strong and well-developed medical technology sector is expected to demonstrate the adoption of ISH-type technologies. Thus, it is projected that the market for in situ hybridization will grow in the region due to the rising prevalence of cancer and the growing acceptability of cutting-edge medical technology.
The Germany market dominated the Europe In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $114.7 million by 2028.The UK market is anticipated to grow at a CAGR of 5.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.2% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
By End Use
- Research & Diagnostic Laboratories
- Academic Institutes
- CROs
- Others
By Application
- Cancer
- Cytogenetics
- Developmental Biology
- Infectious Diseases
- Others
By Product
- Instruments
- Kits & Probes
- Software
- Services
By Probe
- DNA
- RNA
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Abbott Laboratories
- PerkinElmer, Inc
- Agilent Technologies, Inc
- Merck Group
- Bio-Rad Laboratories, Inc
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd
- Neogenomics, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe In Situ Hybridization Market, by Technology
1.4.2 Europe In Situ Hybridization Market, by End Use
1.4.3 Europe In Situ Hybridization Market, by Application
1.4.4 Europe In Situ Hybridization Market, by Product
1.4.5 Europe In Situ Hybridization Market, by Probe
1.4.6 Europe In Situ Hybridization Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe In Situ Hybridization Market by Technology
3.1 Europe Fluorescent In Situ Hybridization (FISH) Market by Country
3.2 Europe Chromogenic In Situ Hybridization (CISH) Market by Country
Chapter 4. Europe In Situ Hybridization Market by End-use
4.1 Europe Research & Diagnostic Laboratories Market by Country
4.2 Europe Academic Institutes Market by Country
4.3 Europe CROs Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe In Situ Hybridization Market by Application
5.1 Europe Cancer Market by Country
5.2 Europe Cytogenetics Market by Country
5.3 Europe Developmental Biology Market by Country
5.4 Europe Infectious Diseases Market by Country
5.5 Europe Others Market by Country
Chapter 6. Europe In Situ Hybridization Market by Product
6.1 Europe Instruments Market by Country
6.2 Europe Kits & Probes Market by Country
6.3 Europe Software Market by Country
6.4 Europe Services Market by Country
Chapter 7. Europe In Situ Hybridization Market by Probe
7.1 Europe DNA Market by Country
7.2 Europe RNA Market by Country
Chapter 8. Europe In Situ Hybridization Market by Country
8.1 Germany In Situ Hybridization Market
8.1.1 Germany In Situ Hybridization Market by Technology
8.1.2 Germany In Situ Hybridization Market by End-use
8.1.3 Germany In Situ Hybridization Market by Application
8.1.4 Germany In Situ Hybridization Market by Product
8.1.5 Germany In Situ Hybridization Market by Probe
8.2 UK In Situ Hybridization Market
8.2.1 UK In Situ Hybridization Market by Technology
8.2.2 UK In Situ Hybridization Market by End-use
8.2.3 UK In Situ Hybridization Market by Application
8.2.4 UK In Situ Hybridization Market by Product
8.2.5 UK In Situ Hybridization Market by Probe
8.3 France In Situ Hybridization Market
8.3.1 France In Situ Hybridization Market by Technology
8.3.2 France In Situ Hybridization Market by End-use
8.3.3 France In Situ Hybridization Market by Application
8.3.4 France In Situ Hybridization Market by Product
8.3.5 France In Situ Hybridization Market by Probe
8.4 Russia In Situ Hybridization Market
8.4.1 Russia In Situ Hybridization Market by Technology
8.4.2 Russia In Situ Hybridization Market by End-use
8.4.3 Russia In Situ Hybridization Market by Application
8.4.4 Russia In Situ Hybridization Market by Product
8.4.5 Russia In Situ Hybridization Market by Probe
8.5 Spain In Situ Hybridization Market
8.5.1 Spain In Situ Hybridization Market by Technology
8.5.2 Spain In Situ Hybridization Market by End-use
8.5.3 Spain In Situ Hybridization Market by Application
8.5.4 Spain In Situ Hybridization Market by Product
8.5.5 Spain In Situ Hybridization Market by Probe
8.6 Italy In Situ Hybridization Market
8.6.1 Italy In Situ Hybridization Market by Technology
8.6.2 Italy In Situ Hybridization Market by End-use
8.6.3 Italy In Situ Hybridization Market by Application
8.6.4 Italy In Situ Hybridization Market by Product
8.6.5 Italy In Situ Hybridization Market by Probe
8.7 Rest of Europe In Situ Hybridization Market
8.7.1 Rest of Europe In Situ Hybridization Market by Technology
8.7.2 Rest of Europe In Situ Hybridization Market by End-use
8.7.3 Rest of Europe In Situ Hybridization Market by Application
8.7.4 Rest of Europe In Situ Hybridization Market by Product
8.7.5 Rest of Europe In Situ Hybridization Market by Probe
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.2 Abbott Laboratories
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PerkinElmer, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Agilent Technologies, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.6 Bio-Rad laboratories, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expenses
9.7 Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Danaher Corporation (Leica Biosystems)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.9 F. Hoffmann-La Roche Ltd.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.10. Neogenomics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd.
- Neogenomics, Inc.
Methodology
LOADING...
